09:00 - 10:00
Digital therapeutics and their impact on socie
In the 20th century we have been able to increase the average lifespan by 25 years, but there has not been a matching increase in healthspan. We are living longer, but our quality of life has not increased. There is an explosive, bordering on unmanageable increase in chronic diseases across the world, including, cardiovascular disease, smoking and alcohol related health issues, diabetes, Alzheimer’s, obesity, asthma and stroke. The increase in these diseases is not just in affluent populations, but also poorer countries, as well as occurring earlier in life. The World Health Organisation reports that by 2020 chronic diseases will account for three quarters of all deaths worldwide, and they are a major factor in the reduction of quality life for these patients and their care givers. Healthcare systems also experience the burden of providing services efficiently and effectively. The cost of managing co-morbid chronic patients is estimated to be eight times that of a relatively healthy patient.
The use of digital therapeutics is far and wide, and continuing to grow, albeit with varying degrees of complexity and success. Many are based on tracking, shaping behavior, and data collection as their basis for delivering positive outcomes alongside companion services and healthcare professionals. The digital therapeutics that are proven to deliver to their claimed outcomes can make the most impact to healthspan in the prevention, intervention and management of chronic diseases, reducing the burden on healthcare systems, increasing the quality of life for patients and their caregivers, and supporting healthcare professionals.
Elisa del Galdo | Head of Customer Experience